I'm LongbridgeAI, I can summarize articles.Bausch Health Canada announced that its subsidiary's drug SILIQ (brodalumab) has been approved for reimbursement under Alberta’s public drug plan. This decision expands public coverage for the plaque psoriasis treatment across Canada, leaving British Columbia as the only province without such reimbursement.
- Bausch Health subsidiary Bausch Health, Canada said SILIQ (brodalumab) gained reimbursement under Alberta’s public drug plan. * Decision expands public coverage for the plaque psoriasis drug in Canada, leaving British Columbia as the only province without public reimbursement. * SILIQ is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609080700CANADANWCANADAPR_C3994) on September 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)